MNG1018
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.424
- E2F_TARGETS+0.416
- UV_RESPONSE_DN+0.406
- TGF_BETA_SIGNALING+0.357
- MITOTIC_SPINDLE+0.323
- MYC_TARGETS_V1+0.317
- HEDGEHOG_SIGNALING+0.284
- MYC_TARGETS_V2+0.265
- DNA_REPAIR+0.242
- NOTCH_SIGNALING+0.241
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.405
- APICAL_SURFACE-0.402
- IL6_JAK_STAT3_SIGNALING-0.399
- TNFA_SIGNALING_VIA_NFKB-0.368
- ALLOGRAFT_REJECTION-0.342
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.332
- COMPLEMENT-0.317
- MTORC1_SIGNALING-0.312
- KRAS_SIGNALING_UP-0.294
- COAGULATION-0.289
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.893 |
| 2 | SRR934847 | — | — | 0.868 |
| 3 | 4549956C-8D25-4B37-894C-E82D5C7684F0 | — | — | 0.867 |
| 4 | TCGA-XF-AAN7-01A-11R-A42T-07 | — | — | 0.851 |
| 5 | SRR934951 | — | — | 0.851 |
| 6 | SRR934823 | — | — | 0.848 |
| 7 | TCGA-77-8139-01A-11R-2247-07 | — | cohortSQ1 | 0.845 |
| 8 | SRR9879265 | — | cohortMD1 | 0.838 |
| 9 | ERR2208889 | — | — | 0.837 |
| 10 | SRR10900568 | — | — | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.424 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.416 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.406 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.357 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.323 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.317 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.284 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.265 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.242 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.241 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.217 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.193 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.133 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.081 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.042 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.021 | Inavolisib | — uncovered |